174 related articles for article (PubMed ID: 32816945)
1. HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome.
Rosenbaum E; Seier K; Bandlamudi C; Dickson M; Gounder M; Keohan ML; Chi P; Kelly C; Movva S; Nacev B; Simeone N; Donoghue M; Slotkin EK; Qin LX; Antonescu CR; Tap WD; D'Angelo SP
Clin Cancer Res; 2020 Oct; 26(20):5448-5455. PubMed ID: 32816945
[TBL] [Abstract][Full Text] [Related]
2. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.
Robbins PF; Kassim SH; Tran TL; Crystal JS; Morgan RA; Feldman SA; Yang JC; Dudley ME; Wunderlich JR; Sherry RM; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Li YF; El-Gamil M; Rosenberg SA
Clin Cancer Res; 2015 Mar; 21(5):1019-27. PubMed ID: 25538264
[TBL] [Abstract][Full Text] [Related]
3. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
4. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
Robbins PF; Morgan RA; Feldman SA; Yang JC; Sherry RM; Dudley ME; Wunderlich JR; Nahvi AV; Helman LJ; Mackall CL; Kammula US; Hughes MS; Restifo NP; Raffeld M; Lee CC; Levy CL; Li YF; El-Gamil M; Schwarz SL; Laurencot C; Rosenberg SA
J Clin Oncol; 2011 Mar; 29(7):917-24. PubMed ID: 21282551
[TBL] [Abstract][Full Text] [Related]
5. Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor.
Joseph J; Nathenson MJ; Trinh VA; Malik K; Nowell E; Carter K; Weathers SP; Demetri GD; Araujo D; Conley AP
J Immunother Cancer; 2019 Nov; 7(1):296. PubMed ID: 31703609
[TBL] [Abstract][Full Text] [Related]
6. Human Leukocyte Antigen-A Allele Distribution in Nasopharyngeal Carcinoma Patients Showing Anti-Melanoma-Associated Antigen A or Synovial Sarcoma X-2 T Cell Response in Blood.
Fan PW; Huang L; Chang XM; Feng YN; Yao X; Peng YC; Dong T; Wang RZ
Chin Med J (Engl); 2018 Jun; 131(11):1289-1295. PubMed ID: 29786040
[TBL] [Abstract][Full Text] [Related]
7. HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15.
Garrido MA; Rodriguez T; Zinchenko S; Maleno I; Ruiz-Cabello F; Concha Á; Olea N; Garrido F; Aptsiauri N
Immunogenetics; 2018 Nov; 70(10):647-659. PubMed ID: 30145665
[TBL] [Abstract][Full Text] [Related]
8. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.
Khong HT; Yang JC; Topalian SL; Sherry RM; Mavroukakis SA; White DE; Rosenberg SA
J Immunother; 2004; 27(6):472-7. PubMed ID: 15534491
[TBL] [Abstract][Full Text] [Related]
9. Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma.
Sato Y; Nabeta Y; Tsukahara T; Hirohashi Y; Syunsui R; Maeda A; Sahara H; Ikeda H; Torigoe T; Ichimiya S; Wada T; Yamashita T; Hiraga H; Kawai A; Ishii T; Araki N; Myoui A; Matsumoto S; Umeda T; Ishii S; Kawaguchi S; Sato N
J Immunol; 2002 Aug; 169(3):1611-8. PubMed ID: 12133991
[TBL] [Abstract][Full Text] [Related]
10. Identification of new NY-ESO-1 epitopes recognized by CD4+ T cells and presented by HLA-DQ B1 03011.
Karbach J; Pauligk C; Bender A; Gnjatic S; Franzmann K; Wahle C; Jäger D; Knuth A; Old LJ; Jäger E
Int J Cancer; 2006 Feb; 118(3):668-74. PubMed ID: 16152624
[TBL] [Abstract][Full Text] [Related]
11. Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma.
He M; Abro B; Kaushal M; Chen L; Chen T; Gondim M; Yan W; Neidich J; Dehner LP; Pfeifer JD
Hum Pathol; 2020 Jun; 100():15-23. PubMed ID: 32387103
[TBL] [Abstract][Full Text] [Related]
12. Histology and grading are important prognostic factors in synovial sarcoma.
Bianchi G; Sambri A; Righi A; Dei Tos AP; Picci P; Donati D
Eur J Surg Oncol; 2017 Sep; 43(9):1733-1739. PubMed ID: 28579008
[TBL] [Abstract][Full Text] [Related]
13. Engineered T Cells in Synovial Sarcoma: Persistence Pays Off!
Keung EZ; Tawbi HA
Cancer Discov; 2018 Aug; 8(8):914-917. PubMed ID: 30076141
[No Abstract] [Full Text] [Related]
14. Prognostic impact of the tumor immune microenvironment in synovial sarcoma.
Oike N; Kawashima H; Ogose A; Hotta T; Hatano H; Ariizumi T; Sasaki T; Yamagishi T; Umezu H; Endo N
Cancer Sci; 2018 Oct; 109(10):3043-3054. PubMed ID: 30133055
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune thyroid disease elicited by NY-ESO-1 vaccination.
Vita R; Guarneri F; Agah R; Benvenga S
Thyroid; 2014 Feb; 24(2):390-4. PubMed ID: 23590991
[TBL] [Abstract][Full Text] [Related]
16. Current status of engineered T-cell therapy for synovial sarcoma.
Dallos M; Tap WD; D'Angelo SP
Immunotherapy; 2016 Sep; 8(9):1073-80. PubMed ID: 27485079
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.
Mazzaferro V; Coppa J; Carrabba MG; Rivoltini L; Schiavo M; Regalia E; Mariani L; Camerini T; Marchianò A; Andreola S; Camerini R; Corsi M; Lewis JJ; Srivastava PK; Parmiani G
Clin Cancer Res; 2003 Aug; 9(9):3235-45. PubMed ID: 12960108
[TBL] [Abstract][Full Text] [Related]
18. Clinical and genetic determinants of ovarian metastases from colorectal cancer.
Ganesh K; Shah RH; Vakiani E; Nash GM; Skottowe HP; Yaeger R; Cercek A; Lincoln A; Tran C; Segal NH; Reidy DL; Varghese A; Epstein AS; Sonoda Y; Chi D; Guillem J; Temple L; Paty P; Hechtman J; Shia J; Weiser M; Aguilar JG; Kemeny N; Berger MF; Saltz L; Stadler ZK
Cancer; 2017 Apr; 123(7):1134-1143. PubMed ID: 27875625
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma.
Stadtmauer EA; Faitg TH; Lowther DE; Badros AZ; Chagin K; Dengel K; Iyengar M; Melchiori L; Navenot JM; Norry E; Trivedi T; Wang R; Binder GK; Amado R; Rapoport AP
Blood Adv; 2019 Jul; 3(13):2022-2034. PubMed ID: 31289029
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing survival in metastatic synovial sarcoma: importance of patterns of metastases and the first-line chemotherapy regimen.
Salah S; Yaser S; Salem A; Al Mousa A; Abu Sheikha A; Sultan I
Med Oncol; 2013; 30(3):639. PubMed ID: 23780657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
